相关临床试验
18
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1796
进行中（未招募）
1
5.6%
已完成
5
27.8%
Enrolling By Invitation
2
11.1%
尚未招募
6
33.3%
Unknown
4
22.2%
暂无批准数据
- Gene Solutions has secured patent publication (WO 2025 168944 A1) for its breakthrough mitochondrial therapy platform targeting neurological diseases including Alzheimer's and Parkinson's disease. - The company has developed DNA-binding polyamides (DBPAs) that exhibit greater than 90-fold selectivity for mutated DNA sequences over wild-type sequences in mitochondrial genes. - The patented platform covers novel therapeutic lead candidate compounds that target mitochondrial dysfunction by recognizing and downregulating transcription of defective genes. - The technology addresses a critical unmet need in neurological diseases where mitochondrial dysfunction compromises cellular energy production below critical thresholds.
- ScreenIn3D, a University of Strathclyde spin-out, has raised £750,000 in seed funding led by TRICAPITAL Angels to advance its groundbreaking lab-on-a-chip system for cancer drug testing. - The technology enables drug developers to test dozens of cancer therapies on tiny patient-derived tumor samples, offering a faster and more accurate alternative to animal testing. - The platform dramatically increases the number of drug tests possible on precious human tissue samples, potentially reducing clinical trial failures and accelerating time to market for new therapies. - The company plans to expand beyond cancer into women's health, immune therapies, and fertility treatment while growing its workforce from five to eight employees.
